share_log
Benzinga ·  May 9 07:09
Xeris Biopharma Raises FY24 Total Revenue Outlook To $175M-$200M Vs. 184.43M Estimate (Prior View: $170M-$200M)
Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment